NASDAQHealth CareHealthcare PlansSnapshot 2026-07-23
Reading PGNY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity with a focus on revenue expansion. The current thesis remains intact, supported by strong recent financial performance, but confidence is low due to potential sector volatility.
The market seems to have priced in a neutral valuation, with expectations slightly below current performance. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Management is on track to meet its revenue growth target for 2026, having shown strong progress in recent quarters. However, there is a mixed outlook for adjusted EBITDA, and the near-term risk of missing earnings is low but noteworthy due to past performance.
The long-term thesis hinges on the performance of sector bellwethers like UNH, CVS, and ELV. Their ability to meet or exceed earnings expectations will significantly impact PGNY's trajectory.
Overall, PGNY's fundamentals are solid, but the investment carries risks tied to the broader healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that financial performance remains strong and in the top half of its industry. There are currently no identified threats to the thesis.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Revenue growth is crucial for the company’s long-term goals. It shows how well the business is doing.
Confirms:Q2 2026 revenue growth is reported above 10% year over year.
Disproves:Q2 2026 revenue growth drops below 5% year over year.
Why it matters: Confirming revenue guidance of $342M to $355M shows demand stability and growth.
Confirms:Q2 2026 revenue reported within the guidance range of $342M to $355M.
Disproves:Q2 2026 revenue reported below $342M.
Why it matters: Higher net income shows that Progyny is managing costs well. This can boost investor confidence.
Confirms:Net income for Q2 increases year over year by more than 20%.
Disproves:Net income for Q2 grows less than 10% year over year.
Why it matters: Changes in the health care sector growth phase could impact Progyny's performance. The sector has been easing lately.
Confirms:Health care revenue growth drops below its median growth rate.
Disproves:Health care revenue growth stabilizes or improves above its median growth rate.
Why it matters: High member engagement helps make more money. It shows demand for Progyny's services.
Confirms one read:Member engagement was at or above normal levels for this time of year.
Confirms the other:Member engagement was below normal levels for this time of year.
Why it matters: Updates on the $200 million share buyback could affect stock value and investor confidence.
Confirms:The company says it has bought back a large part of the $200 million share buyback.
Disproves:There are no updates or signs of share buybacks in the next quarter.
Why it matters: Progyny's gross profit keeps growing. This shows the company is getting better at its work.
Confirms:Gross profit for Q2 increases year over year by more than 10%.
Disproves:Gross profit for Q2 grows less than 5% year over year.
Why it matters: If revenue growth drops, it may indicate challenges in the business. This could affect investor sentiment.
Confirms:Revenue growth falls below the sector median of 5% year over year.
Disproves:Revenue growth remains above the sector median.
Why it matters: Adjusted EBITDA of $58M to $62M shows the company is running well and making money.
Confirms:Adjusted EBITDA reported within the range of $58M to $62M.
Disproves:Adjusted EBITDA is below $58M.
Why it matters: A new buyback program shows that management believes in the company's worth.
Confirms:Announcement of a new share repurchase program after May 2026.
Disproves:No news or sign of a new share buyback program.
Why it matters: Court approval would fix governance problems and boost investor trust.
Confirms:The court has approved the settlement for the derivative action.
Disproves:Court denies the settlement or delays the approval process.
